Physician profile
Elizabeth John
NPI 1922441468
$1,711.55
in general payments reported to CMS, 2019-2025
21 companies · $297 in 2025
The $297 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $486 · 2023: $471 · 2024: $458 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.59 |
| Education | $164.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $612.14 | 2022-2024 | Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $310.16 | 2023-2024 | Opdivo |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | |
| Genzyme Corporation | $107.14 | 2024 | |
| Seagen INC. | $83.99 | 2023 | |
| Pfizer INC. | $60.83 | 2025 | |
| Astellas Pharma US INC | $45.24 | 2025 | Vyloy |
| Adaptive Biotechnologies Corporation | $43.22 | 2023-2024 | Clonoseq |
| Celgene Corporation | $40.58 | 2023 | Pomalyst |
| Gilead Sciences, INC. | $40.50 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $29.39 | 2024 | Livtencity |
| Regeneron Healthcare Solutions, INC. | $26.62 | 2025 | Dupixent |
| Acrotech Biopharma INC. | $25.43 | 2023 | Beleodaq |
| Janssen Biotech, INC. | $23.47 | 2025 | Balversa, Akeega, Erleada |
| Novartis Pharmaceuticals Corporation | $23.25 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.27 | 2024 | Keytruda |
| Sobi, INC | $21.22 | 2025 | |
| Beone Medicines USA, INC. | $19.76 | 2025 | Tevimbra |
| Abbvie INC. | $18.03 | 2025 | |
| Novocure INC. | $17.74 | 2025 | Optune Lua (Novottf-200t) |
| Pharmaessentia USA Corporation | $16.57 | 2024 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.